

SMi present the 18<sup>th</sup> annual conference...

## **Superbugs & Superdrugs**

16-17 March 2016

Holiday Inn Kensington Forum

<http://www.superbugssuperdrugs.com/inderscience>

**#SMISUPERBUGS**

---

Antimicrobial resistance (AMR) is clearly a serious global threat. To combat potential epidemic, requires both industry and government collaboration on an international level in antibiotics R&D investments, preventive measures and emergency response. As new resistance mechanisms rapidly spread throughout the developed and developing nations, this is putting our existing antibiotic pipeline under greater higher risk of failing to resolve many standard medical treatments, as well as compromising our achievements in modern standard medicine including cancer therapeutics and surgery.

Expanding horizons on the growing global threat of AMR for almost two decades, Superbugs & Superdrugs will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.

Working with an expert advisory board and an esteemed panel of industry leaders, the new agenda for the 18<sup>th</sup> annual show, will hone in on key topics such as R&D, collaboration, global epidemics, monoclonal anti-bodies, genome sequencing, rapid diagnostic tools, antibiotic alternatives, multi-resistance gram-negative infections, resistance prevention, antimicrobial peptides, combination therapies, microbiodata host interactions, plus much more!

### **Chairs for 2016:**

Richard Bax, Senior Partner, Transcrip Partners

Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd

### **Elite International Speakers Include:**

Line Matthiessen, MD PhD, Head of Unit Fighting Infectious Diseases and Advancing Public Health, European Commission

Melissa Stundick, Chief, Anti-Infectives Programme, BARDA

Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents

Prabhavathi Fernandes, President & CEO, Cempra Pharmaceuticals

Ankit Mahadevia, MD, President & CEO, Spero Therapeutics

Eszter Nagy, Co-founder, President and CSO, Arsanis

Jean de Gunzburg, Chief Scientific Officer, Da Volterra

David Cook, Chief Scientific Officer, Blueberry Therapeutics

Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience Ltd

Steven Boakes, Associate Director of Microbiology, Cantab Anti-Infectives

### **Key Business Benefits to Attend:**

- Network with industry-leading experts on drug and antimicrobial material developments
- Learn new funding opportunities from BARDA and US National plans, to combat antimicrobial resistance

- Understand how the EU Commission's practical approach in R&D can support your business growth
- Reinvigorate business models with Project DRIVE-AB and find workable solutions to strengthen drug development
- Build your antibiotic pipeline with new insights on microbiome profiling to fight multi-resistant gram negative infections
- Hear important discussions on tackling major bottlenecks that hinder development of new antimicrobial drugs with our star panel line-up

For further details and to register, visit the website at

<http://www.superbugssuperdrugs.com/inderscience> or contact the team on +44 (0)20 7827 6000.